Veröffentlichungsdatum: 15 Juli 2009
Projektträger – zwischengeschaltetes Finanzinstitut
A leading pharmaceutical company carrying out internationally reputable research and development activities.
Ort
Beschreibung
The project concerns the research and development activities of a major European pharmaceutical company mainly aimed at the clinical development of novel cardiology drugs addressing an existing unmet need. Additionally, it comprises the pre-clinical development of early-stage compounds, as well as efforts associated with the regulatory approval process.
Ziele
The project supports the development of new drugs for the treatment of cardiovascular diseases.
Sektor(en)
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 500 million.
Gesamtkosten (voraussichtlicher Betrag)
EUR 1130 million.
Umweltaspekte
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA, therefore, is not required by EU Directive 97/11 amended by Directive 2003/35. By the very nature of activities involved and the location of the sites, impact on the biodiversity of terrestrial, freshwater and marine environments will be negligible.
Auftragsvergabe
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. The project will be mostly implemented by experienced staff within in the promoter’s existing R&D organization, in co-operation with university hospitals and specialised contract service providers. The promoter has sound procedures for procuring specialised equipment and external services. These procedures are in the best interest of the project and satisfactory to the Bank.
Projektstatus
Unterzeichnet - 24/06/2010
Haftungsausschluss
Bis Finanzierungen vom Verwaltungsrat genehmigt und anschließend unterzeichnet werden, befinden sich die Projekte in der Prüfungs- oder Verhandlungsphase. Die Angaben auf dieser Seite sind daher unverbindlich.
Sie dienen lediglich der Transparenz und stellen nicht die offizielle EIB-Politik dar (vgl. auch die erklärenden Anmerkungen).